Erlotinib intermediates is a reversible inhibitor of small molecule epidermal factor receptor tyrosine kinase and is mainly used for the treatment of second-line or third-line treatment of locally advanced or metastatic non-small cell lung cancer and treatment of pancreatic cancer.
Erlotinib intermediates Applications:
Non-small cell lung cancer, pancreatic cancer, block signal transduction of tumor cells, interfere with cell proliferation, differentiation and other processes inhibit the growth of tumor cells and induce apoptosis;
Second-line treatment of locally advanced or metastatic non-small cell lung cancer. Recently, it has been approved by the FDA and can be combined with gemcitabine as first-line treatment of advanced pancreatic cancer.
Second and third grade drugs for the treatment of non-small cell lung cancer
